Professor of Medicine, Johns Hopkins University School of Medicine; Medical Director, Viral Hepatitis Center
Infectious Disease
Dr. Mark Sulkowski, MD
|
|
Give Review
Mark Sulkowski practices Infectious Disease. He went to Temple University School of Medicine. He over the years received 1 awards: "Elected Member". Dr. Mark Sulkowski is also a published doctor. He has 32 publication published. The most recent publication is: Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. He is registered with Medicare and accepts Medicare payments.
Publications
- Public health clinic-based hepatitis C testing and linkage to care in baltimore.
- Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients.
- Effectiveness of Simeprevir plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients with HCV Genotype 1 Infection.
- Extrahepatic Morbidity and Mortality of Chronic Hepatitis C.
- Safety and Efficacy of Ledipasvir-Sofosbuvir in African Americans with Hepatitis C Virus Infection: A Retrospective Analysis of Phase 3 Data.
- Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
- Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
- Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
- Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C vi...
- Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection.
- VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
- IP-10 Kinetics in Treatment-Naïve Versus -Experienced Patients Receiving Interferon-Free Hepatitis C Virus Therapy: Implications for the Innate Immune Response.
- Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
- Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin.
- Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients.
- Infections During Peginterferon/Ribavirin Therapy Are Associated With the Magnitude of Decline in Absolute Lymphocyte Count: Results of the IDEAL Study.
- All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naive Patients with Genotype 1 HCV Infection.
- Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.
- The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.
- Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV- Infected Adults: A Randomized, Double-Blind, Phase 1b Study.
- Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals.
- Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blin...
- Faldaprevir combined with peginterferon Alfa-2a and ribavirin in chronic HCV genotype-1 patients with prior nonresponse: SILEN-C2 trial.
- Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection.
- HCV therapy in HIV-infected patients.
- Faldaprevir combined with peginterferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype-1 HCV: SILEN-C1 trial.
- Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.
- Hepatitis C virus infection in HIV-infected patients.
- Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.
- Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial.
Schools
Temple University
Duke University
Johns Hop Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Elected Member
Education
-
Johns Hopkins University -
Duke University Hospital -
Temple University School of Medicine
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1790715423 | |
| NPPES Provider LastName | SULKOWSKI | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 139.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1790715423 |
| Last Name Of The Provider | SULKOWSKI |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Manjari G. Joshi, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Atiq U. Rahman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Chandralekha Banerjee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Naomi O'Grady, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Shelley S. Magill, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Maria A. Said, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amita Gupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ulrike K. Buchwald, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Krirk Asavametha, MD |
|
|
Dr. Kris A. Oursler, MD
This Doctor is OpenDoctor Recommended.
|